Latest filings (excl ownership)
10-Q
2024 Q1
Quarterly report
14 May 24
8-K
Gain Therapeutics Reports Financial Results for First Quarter 2024 and Provides Corporate Update
14 May 24
ARS
2023 FY
Annual report to shareholders
26 Apr 24
DEFA14A
Additional proxy soliciting materials
26 Apr 24
DEF 14A
Definitive proxy
26 Apr 24
8-K
Gain Therapeutics Bolsters Management Team with the Appointment of Gene Mack as Chief Financial Officer
8 Apr 24
10-K
2023 FY
Annual report
26 Mar 24
8-K
Gain Therapeutics Reports Financial Results for Year End 2023 and Provides Corporate Update
26 Mar 24
8-K
Departure of Directors or Certain Officers
22 Feb 24
8-K
Gain Therapeutics’ Ceo Matthias Alder Issues Letter to Shareholders and Provides Operational Update
31 Jan 24
424B3
Prospectus supplement
2 Jan 24
EFFECT
Notice of effectiveness
2 Jan 24
CORRESP
Correspondence with SEC
22 Dec 23
UPLOAD
Letter from SEC
21 Dec 23
S-1
IPO registration
19 Dec 23
424B5
Prospectus supplement for primary offering
24 Nov 23
8-K
Gain Therapeutics Announces Proposed Public Offering
22 Nov 23
424B5
Prospectus supplement for primary offering
20 Nov 23
8-K
Termination of a Material Definitive Agreement
17 Nov 23
10-Q
2023 Q3
Quarterly report
14 Nov 23
8-K
Gain Therapeutics Announces Third Quarter 2023 Financial Results and Business Update
14 Nov 23
10-Q
2023 Q2
Quarterly report
10 Aug 23
8-K
Gain Therapeutics Announces Second Quarter 2023 Financial Results and Business Update
10 Aug 23
8-K
Submission of Matters to a Vote of Security Holders
23 Jun 23
S-8
Registration of securities for employees
26 May 23
10-Q
2023 Q1
Quarterly report
12 May 23
8-K
Gain Therapeutics Reports First Quarter 2023 Financial Results and Business Update
12 May 23
DEFA14A
Additional proxy soliciting materials
28 Apr 23
DEF 14A
Definitive proxy
28 Apr 23
8-K
Departure of Directors or Certain Officers
28 Apr 23
ARS
2022 FY
Annual report to shareholders
28 Apr 23
8-K
Gain Therapeutics Appoints C. Evan Ballantyne as Chief Financial Officer
12 Apr 23
10-K
2022 FY
Annual report
23 Mar 23
8-K
Gain Therapeutics Reports Full Year 2022 Financial Results and Business Update
23 Mar 23
8-K
Departure of Directors or Certain Officers
16 Dec 22
10-Q
2022 Q3
Quarterly report
10 Nov 22
8-K
Gain Therapeutics, Inc. Reports Third Quarter 2022 Financial Results and Business Update
10 Nov 22
8-K
GAIN THERAPEUTICS Announces PROMOTION OF Matthias Alder TO chief executive officer
20 Sep 22
10-Q
2022 Q2
Quarterly report
8 Aug 22
8-K
GAIN THERAPEUTICS, INC. REPORTS second QUARTER 2022 FINANCIAL RESULTS AND BUSINESS UPDATE
8 Aug 22
Latest ownership filings
4
Gene Mack
8 Apr 24
3
Gene Mack
8 Apr 24
4
Jeffrey Scott Riley
1 Apr 24
4
Matthias Alder
28 Mar 24
4
Gianluca Fuggetta
25 Mar 24
4
Matthias Alder
25 Mar 24
4
Matthias Alder
22 Dec 23
4
Matthias Alder
14 Dec 23
4
Matthias Alder
3 Oct 23
4
ERIC I RICHMAN
22 Sep 23
4
Matthias Alder
22 Sep 23
4
Matthias Alder
5 Jul 23
4
Khalid Islam
26 Jun 23
4
Jeffrey Scott Riley
26 Jun 23
4
DOV A MD GOLDSTEIN
26 Jun 23
4
Gwen A Melincoff
26 Jun 23
4
Claude Nicaise
26 Jun 23
4
HANS PETER HASLER
26 Jun 23
4
Charles Evan Ballantyne
12 Apr 23
3
Charles Evan Ballantyne
12 Apr 23
4
Salvatore Calabrese
27 Mar 23
4
Gianluca Fuggetta
27 Mar 23
4
Matthias Alder
27 Mar 23
3
Gianluca Fuggetta
21 Dec 22
4
ERIC I RICHMAN
22 Sep 22
4
Khalid Islam
22 Sep 22
4
Jeffrey Scott Riley
22 Sep 22
4
DOV A MD GOLDSTEIN
22 Sep 22
4
Gwen A Melincoff
22 Sep 22
4
Claude Nicaise
22 Sep 22
4
HANS PETER HASLER
22 Sep 22
4
Matthias Alder
22 Sep 22
4
Salvatore Calabrese
19 Jul 22
4
Matthias Alder
19 Jul 22
4
ERIC I RICHMAN
27 May 22
4
ERIC I RICHMAN
23 May 22
4/A
Salvatore Calabrese
23 May 22
4
Salvatore Calabrese
19 May 22
4/A
ERIC I RICHMAN
21 Apr 22
3/A
ERIC I RICHMAN
21 Apr 22